Union Defence Minister Rajnath Singh on Monday, 13 July 2026, praised the growth of India's healthcare sector under Prime Minister Narendra Modi, highlighting advances ranging from affordable healthcare access to cutting-edge indigenous medical technologies including gene therapy and CAR-T Cell Therapy.

Posting on X, Singh wrote: 'प्रधानमंत्री @narendramodi के नेतृत्व में भारत का Health System आत्मनिर्भर और जन-केंद्रित बनकर उभरा है' — 'Under the leadership of Prime Minister Narendra Modi, India's health system has emerged as self-reliant and people-centric.' He added that the country is 'scaling new heights in the health sector,' spanning affordable healthcare, indigenous medical technologies, gene therapy, CAR-T Cell Therapy, and medical research.

Context

The post reflects a broader government narrative around Atmanirbhar Bharat — the self-reliance mission — being extended to the healthcare domain. India's push for health-sector self-sufficiency gained significant momentum after the COVID-19 pandemic exposed vulnerabilities in import-dependent supply chains for drugs, devices, and critical equipment. Singh's remarks signal the ruling dispensation's intent to project healthcare autonomy as a political and policy achievement.

CAR-T Cell Therapy — Chimeric Antigen Receptor T-Cell Therapy — is an advanced immunotherapy used primarily in cancer treatment. Indian research institutions have been working on developing affordable, indigenous versions of this therapy, which is prohibitively expensive when imported from abroad.

Policy Backdrop

Several flagship initiatives underpin the claims made in Singh's post. The Ayushman Bharat Pradhan Mantri Jan Arogya Yojana, launched in 2018, extended health insurance coverage to low-income households, forming the bedrock of the 'affordable healthcare' narrative. The National Health Policy 2017 set targets for raising public health expenditure and strengthening domestic medical research capacity.

On the manufacturing side, the Production Linked Incentive (PLI) scheme for pharmaceuticals and medical devices, rolled out in 2020, aimed to reduce import dependence and incentivise domestic production. Together, these schemes form the policy architecture that the government credits for India's growing self-reliance in healthcare.

Stakeholders and Impact

The most direct beneficiaries of affordable healthcare expansion are low- and middle-income patients, particularly those in rural and semi-urban India who previously lacked access to insurance or specialist care. If indigenous CAR-T and gene therapies reach commercial viability, they could dramatically reduce treatment costs for cancer patients who currently rely on expensive imported options.

Medical researchers, academic institutions, and domestic pharmaceutical companies also stand to gain from increased policy focus and potential budget allocations toward high-end R&D. Healthcare providers — from primary health centres to tertiary hospitals — are central to translating these policy gains into on-ground outcomes.

What's Next

Observers will watch the next Union Budget closely for health research allocations and any new regulatory approvals for indigenous gene or CAR-T therapies. Parliamentary discussions on whether advanced treatments such as gene therapy should be brought under public insurance schemes like Ayushman Bharat are likely to intensify. Singh's statement, coming from a senior Cabinet minister, may also be read as a signal ahead of policy announcements in the health sector.

As India positions itself as a global hub for affordable, high-quality healthcare — from generics to frontier therapies — the political stakes around delivering on that promise to ordinary citizens will only rise.